Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer

Advances in Experimental Medicine and Biology

Volumn 882, Issue , 2016, Pages 125-154

  Ma, Cynthia X ^b   Bose, Ron ^b   Ellis, Matthew J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

BCI; Endocrine therapy; EndoPredict; Estrogen receptor positive breast cancer; MammaPrint; Multigene assay; Oncotype Dx; Prognostic markers; Prosigna; Risk of recurrence

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ANALYTICAL EQUIPMENT; BREAST CANCER INDEX; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PROGNOSIS; DIAGNOSTIC EQUIPMENT; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION PROFILING; GENETIC DISORDER; HUMAN; IHCA4+4 SCORE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PREOPERATIVE ENDOCRINE PROGNOSTIC INDEX; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SOMATIC MUTATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ANIMAL; BREAST NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MORTALITY; MUTATION; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MUTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961564492     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-22909-6_5     Document Type: Chapter

References (124)

1. Early Breast Cancer Trialists’ Collaborative G (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
2. Josefsson ML, Leinster SJ (2010) Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: metaanalyses of monotherapy, sequenced therapy and extended therapy. Breast 19:76–83
3. Ellis MJ, Suman V, McCall L et al (2012) Z1031B Neoadjuvant aromatase inhibitor trial: a phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level > 10%. San Antonio Breast Cancer Symposium. San Antonio, Texas, 2012, pp Abstract PD07-01
4. Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 379:432–444
5. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816
6. Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer., ASCO Annual Meeting. Chicago, IL, 2013, pp Abstract 05
7. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802
8. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
9. Sorlie T, Perou C, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874
10. Dowsett M, Smith IE, Ebbs SR et al (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s–958s
11. Dowsett M, Smith IE, Ebbs SR et al (2007) Prognostic value of Ki67 expression after shortterm presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170
12. Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388
13. Ellis MJ, Ding L, Shen D et al (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353–360
14. Toy W, Shen Y, Won H et al (2013) ESR1 ligand-binding domain mutations in hormoneresistant breast cancer. Nat Genet 45:1439–1445
15. Robinson DR, Wu YM, Vats P et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446–1451
16. Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116–1130
17. Zhang QX, Borg A, Wolf DM et al (1997) An estrogen receptor mutant with strong hormoneindependent activity from a metastatic breast cancer. Cancer Res 57:1244–1249
18. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A et al (2013) D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73:6856–6864
19. Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474
20. Khoshnoud MR, Lofdahl B, Fohlin H et al (2011) Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat 126:421–430
21. Molino A, Micciolo R, Turazza M et al (1997) Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45:241–249
22. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816
23. Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
24. Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116
25. McGuire WL, De La Garza M, Chamness GC (1977) Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37:637–639
26. Alberts SR, Ingle JN, Roche PR et al (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78:764–772
27. Elledge RM, Green S, Pugh R et al (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111–117
28. Barnes DM, Harris WH, Smith P et al (1996) Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445–1451
29. Allred DC (2008) Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol 26:2433–2435
30. Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
31. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–e72
32. Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065
33. Mauriac L, Keshaviah A, Debled M et al (2007) Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18:859–867
34. Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846–3852
35. Lal P, Tan LK, Chen B (2005) Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3655 invasive breast carcinomas. Am J Clin Pathol 123:541–546
36. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
37. Pietras RJ, Arboleda J, Reese DM et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435–2446
38. Oh AS, Lorant LA, Holloway JN et al (2001) Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15:1344–59
39. Dowsett M, Houghton J, Iden C et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818–826
40. De Placido S, De Laurentiis M, Carlomagno C et al (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039–1046
41. Ellis MJ, Tao Y, Young O et al (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019–3025
42. Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9:23–28
43. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
44. Gerdes J, Schwab U, Lemke H et al (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20
45. Pinder SE, Wencyk P, Sibbering DM et al (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146–149
46. Ellis MJ, Luo J, Tao Y et al (2009) Tumor Ki67 proliferation index within 4 weeks of initiating neoadjuvant endocrine therapy for early identification of non-responders, San Antonio Breast Cancer Symposium. San Antonio, Texas, pp abstract 78
47. Goncalves R, Ma C, Luo J et al (2012) Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol 9:223–229
48. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139
49. Ellis MJ, Coop A, Singh B et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523–6531
50. Ellis MJ, Suman VJ, Hoog J et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol: Off J Am Soc Clin Oncol 29:2342–2349
51. Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757
52. Goss PE, Ingle JN, Pritchard KI et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol 31:1398–1404
53. Ellis MJ, Suman VJ, Hoog J et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2–3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol 29:2342–2349
54. Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Nat Cancer Inst 103:1656–1664
55. Sanati S, Suman VJ, Goncalves R et al (2014) Validation of the preoperative endocrine prognostic index in the ACOSOG (Alliance) Z1031 neoadjuvant aromatase inhibitor trial, San Antonio Breast Cancer Symposium, 2014, pp Abstract P4-11–13
56. Goncalves R, Ma C, Tao Y et al (2013) The development of a standardized Ki-67 assay for the ALTERNATE trial: an experience in academic investigational device development, San Antonio Breast Cancer Symposium, 2013, pp Abstract P3-05–10
57. Cuzick J, Dowsett M, Pineda S et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29:4273–4278
58. Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
59. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423
60. Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70
61. van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009
62. van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
63. Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192
64. Mook S, Schmidt MK, Viale G et al (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295–302
65. Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991
66. Bogaerts J, Cardoso F, Buyse M et al (2006) Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3:540–551
67. Sapino A, Roepman P, Linn SC et al (2014) MammaPrint molecular diagnostics on formalinfixed, paraffin-embedded tissue. J Mol Diagn 16:190–197
68. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N Engl J Med 351:2817–2826
69. Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65
70. Dowsett M, Cuzick J, Wale C et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a transATAC study. J Clin Oncol 28:1829–1834
71. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
72. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721–728
73. Filipits M, Rudas M, Jakesz R et al (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012–6020
74. Dubsky P, Brase JC, Jakesz R et al (2013) The EndoPredict score provides prognostic information on late distant metastases in ER-POSITIVE/HER2-breast cancer patients. Br J Cancer 109:2959–2964
75. Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167
76. Ivshina AV, George J, Senko O et al (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292–10301
77. Loi S, Haibe-Kains B, Desmedt C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246
78. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679
79. University of North Carolina Microarray Database. GEO data sets for breast cancer research published papers (Clinical Data updated on 11-6-2007 for Data I, 4-7-2008 for Data II). https://genome.unc.edu/pubsup/breastGEO/
80. Hess K, Anderson K, Symmans W et al (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 24:4236–4244
81. Nielsen TO, Parker JS, Leung S et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222–5232
82. Chia SK, Bramwell VH, Tu D et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18:4465–4472
83. Nielsen T, Wallden B, Schaper C et al (2014) Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 14:177
84. Geiss GK, Bumgarner RE, Birditt B et al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317–325
85. Reis PP, Waldron L, Goswami RS et al (2011) mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 11:46
86. Dowsett M, Sestak I, Lopez-Knowles E et al (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783–2790
87. Gnant M, Filipits M, Greil R et al (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339–345
88. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Nat Cancer Inst 101:1446–1452
89. Filipits M, Nielsen TO, Rudas M et al (2014) The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 20:1298–1305
90. Sestak I, Cuzick J, Dowsett M et al (2014) Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 33(916):922
91. Jerevall PL, Ma XJ, Li H et al (2011) Prognostic utility of HOXB13[thinsp]:[thinsp]IL-17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104:1762-1769
92. Jankowitz R, Cooper K, Erlander M et al (2011) Prognostic utility of the breast cancer index and comparison to adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res 13:R98
93. Zhang Y, Schnabel CA, Schroeder BE et al (2013) Breast cancer index identifies earlystage estrogen receptor-positive breast cancer patients at risk for early-and late-distant recurrence. Clin Cancer Res 19:4196–4205
94. Sgroi DC, Sestak I, Cuzick J et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breastcancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067–1076
95. Ma CX, Crowder RJ, Ellis MJ (2011) Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 76:750–752
96. Kalinsky K, Jacks LM, Heguy A et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15:5049–5059
97. Maruyama N, Miyoshi Y, Taguchi T et al (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13:408–414
98. Perez-Tenorio G, Alkhori L, Olsson B et al (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13:3577–3584
99. Sanchez CG, Ma CX, Crowder RJ et al (2011) Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13:R21
100. Ellis MJ, Lin L, Crowder R et al (2010) Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119:379–390
101. Goldstein TC, Paull EO, Ellis MJ et al (2013) Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin Cancer Res 19:3114–3120
102. Fuqua SAW, Fitzgerald SD, Chamness GC et al (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51:105–109
103. Roodi N, Bailey LR, Kao WY et al (1995) Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87:446–451
104. Ma Y, Ambannavar R, Stephans J et al (2014) Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues reveals a link to tumor progression. PLoS One 9:e94202
105. Veeraraghavan J, Tan Y, Cao XX et al (2014) Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun 5:4577
106. Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302:774–780
107. Fan P, Agboke FA, McDaniel RE et al (2014) Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer 50:457–468
108. Paul D, Vukelja SJ, Holmes FA et al (2013) Letrozole plus dasatinib improves progressionfree survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Cancer Res 73:S3–07
109. Adelaide J, Finetti P, Charafe-Jauffret E et al (2008) Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 123:2970–2972
110. Holst F, Stahl PR, Ruiz C et al (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39:655–660
111. Vincent-Salomon A, Raynal V, Lucchesi C et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809; author reply 810–812
112. Reis-Filho JS, Drury S, Lambros MB et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809–810; author reply 810–812
113. Horlings HM, Bergamaschi A, Nordgard SH et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:807–808; author reply 810–812
114. Brown LA, Hoog J, Chin SF et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:806–807; author reply 810–812
115. Ooi A, Inokuchi M, Harada S et al (2012) Gene amplification of ESR1 in breast cancers–fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 227:8–16
116. Albertson DG (2012) ESR1 amplification in breast cancer: controversy resolved? J Pathol 227:1–3
117. Holst F, Moelans CB, Filipits M et al (2012) On the evidence for ESR1 amplification in breast cancer. Nat Rev Cancer 12:149
118. Tomita S, Zhang Z, Nakano M et al (2009) Estrogen receptor α gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100:1012–1017
119. Moelans CB, Monsuur HN, de Pinth JH et al (2010) ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst) 33:13–18
120. Moelans CB, Holst F, Hellwinkel O et al (2013) ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. PLoS One 8:e84189
121. Butt AJ, McNeil CM, Musgrove EA et al (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12:S47–S59
122. Fu X, Creighton C, Biswal N et al (2014) Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res 6:430
123. McNeil CM, Sergio CM, Anderson LR et al (2006) c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol 102:147–155
124. Ma XJ, Salunga R, Dahiya S et al (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601–2608